Market Research Blog – Page 860 – New Product Development

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of 9.5% totaling around USD 19.52 Billion by 2033

The global Nucleic Acid And Gene Therapies In Neuromuscular Disorders market size is expected to be valued at USD 7.88 Billion in 2023. With the increasing high incidence of cancer and other target diseases, the overall demand for Nucleic Acid And Gene Therapies In Neuromuscular Disorders is projected to grow at a CAGR of 9.5% between 2023 and 2033, totaling around USD 19.52 Billion by 2033.

The diagnosis of neuromuscular disorders is performed through physical examination as well as certain diagnostic tests. A physician runs a complete medical history assessment to determine if any family member had previously had symptoms of neuromuscular disorders, to assess the condition of a patient.

The global nucleic acid and gene therapies in neuromuscular disorders market is driven by major factors such as rise in government initiatives to ensure early diagnosis, an increase in awareness about genetic disorders, an upsurge in research and development activities, and improvement in healthcare infrastructure.

Factors including the expanding investments by key market players, a strong product portfolio, as well as a high prevalence of target diseases and interest in innovative and new therapy are expected to escalate the market growth in the forthcoming years. In addition, the increased investment in research and development by government and private organizations are anticipated to further create lucrative avenues for the market growth over the analysis period.

In recent years, the rapid technological advancements in cellular and molecular biology in genomics research are other factors that have been contributing greatly to the market growth. The academicians, researchers, and in-house researchers of major market companies with significant funding have all played critical roles.

The frequency of cardiovascular diseases is increasing in many industrialized countries, and there is a growing need to cure these diseases in less time, resulting in players investing extensively in research and development of highly effective and innovative therapeutics such as gene therapy. The prevalence of rare diseases such as cardiovascular and cancer diseases will have positive impact on the demand for gene therapy applications. This in turn is likely to expand the market growth in the near future.

Currently, only a few market players are dominating the market growth, and are significantly contributing to the market’s expansion. The core members who are working on item dispatching and other important coordinated activities to strengthen their market reach globally. In order to increase their cancer gene therapy research and product portfolio, local and small market players are increasingly partnering and developing alliances with large market players.

Key Takeaways from the Market Study

Global Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market was valued at US$ 7.19 Bn by 2022-end
From 2018 to 2022, the market demand expanded at a CAGR of 5%
By Therapy, the Spinal Muscular Atrophy segment of the market constitutes the bulk of the market with a market share of 46%
By Application, the Hospitals segment dominates the market with a share of 45%
From 2023 to 2033, Nucleic Acid And Gene Therapies in Neuromuscular Disorders sales are expected to flourish at a CAGR of 5%.
By 2033, the market value of Nucleic Acid And Gene Therapies in Neuromuscular Disorders is expected to reach US$ 52 Bn.

Increasing research and development, as well as the growing prevalence of neuromuscular disease are the major factors that are expected to accelerate the growth of the Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market during the forecast period, remarks an FMI analyst.

Competitive Landscape

Prominent players in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders market are Pfizer, Inc., F. Hoffmann-La Roche Ltd., UCB Pharma, Biogen, Astellas Pharma, Inc., Novartis AG, Abbott Laboratories, Inc., and Sanofi, among others.

Recent Developments:

In May 2021, Biogen and Capsigen collaborated to discover as well as develop novel AAV Capsids with enhanced properties to facilitate the development of new gene therapies for targeted CNS and Neuromuscular Disorders. Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline. Capsigen received a $15 million upfront payment and is eligible to receive potential research, development and commercial milestone payments.
In June 2019, Vertex Pharmaceuticals Incorporated announced the enhancement of its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics. Vertex and CRISPR Therapeutics had expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of DMD and DM1.

Know More About What the Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market Repost Covers

Future Market Insights offers an unbiased analysis of the global Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market, providing historical data for 2018-2022 and forecast statistics from 2023-2033. To understand opportunities in the Nucleic Acid And Gene Therapies in Neuromuscular Disorders Market, the market is segmented on the basis of disorder, therapy, and application, across five major regions.

A Full Report Overview

Key Segments Covered in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry Analysis

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market by Disorder:

Motor Neuron Diseases
Neuropathies
Neuromuscular Junction Disorders
Myopathies including Muscular Dystrophies

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market by Therapy:

AAV Gene Therapy
Postnatal Gene Therapy
Spinal Muscular Atrophy

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market by Application

Hospitals
Specialty Clinics
Ambulatory Surgery Centers

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market by Region

North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Necrobiosis Lipoidica Diabeticorum Market is projected to reach USD 8.06 Billion by 2033, at a CAGR of 6%

The global Necrobiosis Lipoidica Diabeticorum (NLD) market is expected to be worth USD 4.5 billion in 2023 and USD 8.06 billion by 2033, with a CAGR of 6% from 2023 to 2033. The market for Necrobiosis Lipoidica Diabeticorum (NLD) expanded at a CAGR of 4% between 2017 and 2022.

Diabetes’ rising prevalence can be attributed to the expansion of the Necrobiosis Lipoidica Diabeticorum (NLD) business. According to the International Diabetes Federation, diabetes would be responsible for 6.7 million deaths by 2021. Diabetes is becoming more common in places such as the Middle East and Asia Pacific, fueling the development of NLD. Growth is expected to be bolstered as a result of the presence of untapped growth potential in quickly rising MEA and Asian economies, as well as improved diabetes awareness in these regions.

Key Takeaways from the Market Study

The Necrobiosis Lipoidica Diabeticorum (NLD) market increased at a 4% CAGR from 2017 to 2022.
The global market for Necrobiosis Lipoidica Diabeticorum (NLD) is predicted to increase at a 6% CAGR from 2023 to 2033.
The market for Necrobiosis Lipoidica Diabeticorum (NLD) is estimated to reach $8.06 billion by 2033.
Hospitals have the biggest market share, according to the FMI research.
North America is estimated to have 34% of the market for Necrobiosis Lipoidica Diabeticorum (NLD).
With a CAGR of 5% during the forecast period, the Asia Pacific market is expected to grow significantly throughout the projected period.

“Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in the developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.” says an FMI analyst

Market Competition

Key players in the Necrobiosis Lipoidica Diabeticorum (NLD) market are ALexicare Pharma, Andréas Astier, Mayo Clinic, AbbVie Inc, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., Pfizer, Novartis AG, and GlaxoSmithKline Plc.

Basilea Pharmaceutica Ltd revealed today good topline findings for the Phase III ERADICATE study, investigating ceftobiprole in the treatment of adult patients with Staphylococcus aureus (SAB) bacterial bloodstream infections.
Paladin Labs Inc., a subsidiary of Endo International PLC, launched Xydalba (dalbavancin for injection) in January 2022, a 30-minute intravenous (IV) therapy for acute bacterial skin and skin structure infections (ABSSSI) that can be given in a single or two-dose regimen.

More Insights Available

Geographically, the necrobiosis lipoidica treatment market is concentrated in developed regions, such as North America and Europe, where there is a higher prevalence of the disease due to the higher incidence of diabetes in these regions. However, the market is expected to grow in emerging economies such as India and China, as the prevalence of diabetes increases in these regions.

Overall, the necrobiosis lipoidica market is small but growing, and is expected to continue to grow in the coming years as more treatment options become available and the prevalence of the disease increases.

A Full Report Overview

Key Segments Profiled in the Necrobiosis Lipoidica Diabeticorum (NLD) Industry Survey:

Procedure:

Treatment
- Corticosteroid Creams
- Injected Corticosteroids
- Drugs that Suppress the Immune System
- Anti-inflammatory Drugs
- Medicines that Improve Blood Flow
- Hyperbaric Oxygen Therapy
- Phototherapy
- Laser Therapy

Test Type
- Punch Biopsy
- Glucose Tolerance Test

Application:

Hospitals
Ambulatory Clinics

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Pelvic Cancer Induced Hemorrhegic Cystitis Market to Surpass an Impressive Valuation of USD 11 Billion by 2033, with a CAGR of 18.01%

The global pelvic cancer induced hemorrhagic cystitis market size is estimated to achieve an amazing valuation of USD 2.1 billion in 2023 and reach USD 11 billion by 2033, at a CAGR of 18.01%.

Rising awareness among the population regarding early treatment and diagnosis for related disorders, coupled with the steady shift towards unhealthy diets and sedentary lifestyles, is driving the market demand. Advancements in drug development have enabled physicians to administer drugs directly to the infected tissues without harming surrounding healthy tissues, which has contributed to increasing patient compliance, which in turn is expected to boost industry growth.

The high research and development cost associated with the manufacturing of hemorrahagic cystitis treatment drugs, coupled with increased penetration of generic drugs, is likely to restrain market growth. However, technological advancements in drug development to manufacturing cost-effective and side-effect-free drugs are anticipated to create opportunities for industry movements. Moreover, the use of High approval rate of Ifosfamide and cyclophosphamide for use in a variety of malignancies, both in children and adults are driving the market for Haemorrhagic Cystitis. North America dominates the market for Pelvic Cancer induced Hemorrhagic Cystitis with market valuation of US$ 3.6 Billion, followed by APAC.

Key Takeaways

North American Pelvic cancer induced hemorrhegic cystitis market is expected to reach US$ 3.6 Billion with a CAGR of 14.87% during the forecast period.
With a CAGR of 15.1%, APAC is projected to be fastest growing market for this haemorrhagic cystitis.
By treatment type, chemotherapy is expected to dominate the market with a 2/3^rd segment share.
Radiation therapy is anticipated to be a secondary treatment for hemorrhegic cystitis after Chemotherapy.
High cost of treatments and side-effects in post-treatment period will restrict market growth.
Adoption of combination therapies and novel therapies are expected to proliferate product demand.
Technological advancements in drug development for treatment of pelvic induced hemorrhagic cystitis is anticipated to strengthen market footprint.

“High investments in R&D, advancements in manufacturing drugs, adoption of cost-effective& side-effect-free drugs will open up new avenues for market expansion”- says an FMI Analyst

Competitive Landscape

Key players in the Pelvic cancer induced hemorrhagic Cystitis Market are: Johnson & Johnson Services, Inc, Astellas Pharma Inc, Eli Lilly and Company, Sanofi, Ipsen Pharma, Bayer AG, AstraZeneca, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., Pfizer Inc.

In April 2022, Pfizer made an equity investment worth USD 25 million in Zentalis Pharmaceuticals, Inc. This investment is expected to help Pfizer to leverage its development capabilities globally
In May 2022, Pfizer entered a research collaboration agreement of two years with NetVation DL Medicine. This collaboration is anticipated to aid and advance Pfizer in its research activities
In June 2022, Roche introduced a human papillomavirus (HPV) self-sampling solution that enables patients to perform HPV screening in the presence of a healthcare worker. This is expected to expand the company’s cancer screening solution line-up
In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio.

A Full Report Overview

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023 to 2033.

Key Segments Profiled in the Pelvic Cancer Induced Hemorrhagic Cystitis Market Industry Survey

By Treatment:

Bone Marrow Transplant
Chemotherapy
- Cyclophosphamide
- Ifosfamide
Radiation Therapy
Other Treatments

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Air Ambulance Services Market to Reach a Valuation of USD 19.5 Billion by 2032 is projected to a CAGR of around 12.3%

Air Ambulance Services Market analysis report, global sales of Air Ambulance Services Market in 2021 will be valued at USD 5.5 billion. The market is expected to reach a valuation of USD 19.5 billion by 2032, with a CAGR of 12.3% between 2022 and 2032. The most revenue-generating segment is expected to be rotary-wing air ambulance service, with a CAGR of more than 12.4% between 2022 and 2032.

FMI, in its business report, elaborates the historical and current scenario of the global Air Ambulance Services Market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Air Ambulance Services market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Air Ambulance Services Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Air Ambulance Services market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Air Ambulance Services market.

Following government’s measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMI’s report includes an interesting chapter on preliminary impact of the COVID-19 on the Air Ambulance Services market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

Discounted prices for new customers! Offer expires soon!

Air Ambulance Services Market: Segmentation

Valuable information covered in the FMI’s Air Ambulance Services market report has been segregated into key segments and sub-segments.

By Type:

Rotary-wing
Fixed-wing

By Service Model:

Hospital-based
Community-based

Air Ambulance Services Market: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Air Ambulance Services market. Competitive information detailed in the Air Ambulance Services market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Air Ambulance Services market report.

Key players covered in the report include:

AMR, PHI Air Medical, Babcock Scandinavian Air Ambulance, Express Air Medical Transport, REVA, Inc., Lifeguard Ambulance Service LLC, Acadian Ambulance, IAS Medical, Ltd., and American Air Ambulance

A Full Report Overview

Key Offerings of the Report

Growth Drivers and Opportunities: Comprehensive analysis on growth-driving factors and opportunities for market players in different regional markets
Recent Trends and Forecasts: Detailed assessment on the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
Segmental Analysis: Extensive analysis on each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with necessary information to take critical decisions
Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Air Ambulance Services market

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Hypophospatasia Treatment Market is anticipated to reach USD 26.27 Million by 2033 at a 5.0% of CAGR

The global hypophospatasia treatment market size is expected to be valued USD 16.13 million in 2023. Because of increased alcohol use, global demand for hypophospatasia treatment is predicted to grow at a 5.0% CAGR between 2023 and 2033, reaching approximately USD 26.27 million by 2033. One of the major reasons likely to drive the growth of the Hypophospatasia Treatment Market during the forecast period is an increase in R&D efforts. Furthermore, the ongoing rise in demand for disease-specific innovative treatments is expected to boost market growth in the approaching years.

Furthermore, factors such as increased government and non-profit initiatives in various countries to improve public awareness about rare diseases result in a gradual increase in the diagnosis rate of unusual diseases. As a result, important variables such as favourable reimbursement policies and government finance for treatment in industrialised countries are increasing the rate of acceptance of this therapy. As a result, these factors are expected to add to the market’s revenue share throughout the forecast period.

Other factors that are expected to drive market growth include an increase in the incidence of rare diseases globally, an increase in the demand for Hypophospatasia Drugs to improve the treatment of rare diseases, and an increase in government spending on healthcare infrastructure, such as favourable reimbursement for HPP. Furthermore, the increased availability of HPP therapies and the increased use of HPP drugs influence the market’s revenue share. Moreover, focus on importance of patient safety, increase in the population, growth of awareness, improved healthcare infrastructure, and less stringent guidelines for rare diseases positively affects the growth of the hypophospatasia market. Also, advancements in the HPP therapy as well as government support for treatment extend profitable opportunity to the market players during the analysis period.

Key Takeaways from the Market Study

Global hypophospatasia treatment market was valued at US$ 15.36 Million by 2022-end

From 2018 to 2022, the market demand expanded at a CAGR of 2.6%
By Type, the Odontohypophospatasia segment of the market constitutes the bulk of the market with a market share of 48%
By Treatment Type, the Medication segment dominates the market with a share of 47%
From 2023 to 2033, Hypophospatasia Treatment sales are expected to flourish at a CAGR of 5.0%.
By 2033, the market value of Hypophospatasia Treatment is expected to reach US$ 26.27 Mn.

“An upsurge in financial support to researchers for developing new innovative drugs for treatment of hypophospatasia, coupled with strong product pipeline are expected to fuel the hypophospatasia treatment market over the analysis period,” remarks an FMI analyst.

Competitive Landscape

Prominent players in the hypophospatasia treatment market are Kirin Holdings Company, Vericel Corporation, Mereo BioPharma Group plc., Novartis AG, AM Pharma B.V., Alexion, Bayer AG, Enobia Pharma, and Pfizer, Inc., among others.

Recent Developments:

In November 2022, Rallybio, together with its partner Exscientia, has been working toward the selection of a small molecule development candidate to advance into the clinic targeting ENPP1 for the treatment of patients with hypophospatasia (HPP).
Significant progress has been made to identify a lead compound and generate mouse in vivo biomarker evidence to support modulation of on-target activity. Through this collaboration with a leading global HPP expert, in vivo efficacy data is expected in the second half of 2023. Following those results, both companies expect to commence investigational new drug (IND)-enabling studies.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global Hypophosphatasia Treatment Market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.

To understand opportunities in the Hypophospatasia Treatment Market, the market is segmented on the basis of type, treatment type, and end user, across seven major regions.

A Full Report Overview

Key Segments Covered in the Hypophospatasia Treatment Industry Analysis

Hypophospatasia Treatment Market by Type:

Odontohypophospatasia
Pseudohypophospatasia

Hypophospatasia Treatment Market by Treatment Type:

Medication
- Asfotase Alfa
- Non-steroidal Anti-inflammatory Drugs
- Calcitonin
- Strensiq
Surgery

Hypophospatasia Treatment Market by End User:

Hospitals
Pharmacies
Others

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR

Global Cell and Gene Therapy Clinical Trial Market analysis report, global sales of the Cell and Gene Therapy Clinical Trial Market in 2021 will be worth USD 10.7 billion. The market is expected to reach USD 119.3 billion by 2032, growing at a CAGR of 24.9% between 2022 and 2032. Oncology is forecast to be the biggest revenue-generating segment, with a CAGR of more than 27.9% between 2022 and 2032.

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Cell and Gene Therapy Clinical Trial market.

Over the past decade, healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.

The report offers extensive data sets validating key trends impacting growth in the Cell and Gene Therapy Clinical Trial market. It offers insights into strategies adopted by the key players rise and address the concerns that will challenge the growth of Cell and Gene Therapy Clinical Trial market. With our extensive research and information about the past, current and future market scenario, the Cell and Gene Therapy Clinical Trial market report will help and identify the concerns, for a smooth-sail of the small & medium as well as large enterprises.

Cell and Gene Therapy Clinical Trial Market: Segmentation

By Region

North America
Latin America
Europe
APAC
MEA

Detailed analysis on the geographical region and country wise insights are offered in the latest Cell and Gene Therapy Clinical Trial market report with established market players as well as incumbents in the region.

A Full Report Overview

Market Segments Covered in Cell and Gene Therapy Clinical Trial Market Analysis

By Phase:

Phase I
Phase II
Phase III

By Indication:

Oncology
Cardiology
CNS
Musculoskeletal
Infectious diseases
Dermatology
Endocrine
Metabolic
Genetic
Immunology & Inflammation
Ophthalmology
Hematology
Gastroenterology
Other Indications

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

Competitive Analysis

By Prominent Market Players

Some of the key players in the cell and gene therapy market include IQVIA Holdings Inc., Medpace Holdings Inc., Gilead Sciences, Dendreon, Vericel, Novartis, and Amgen.

With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Cell and Gene Therapy Clinical Trial market

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Age-Related Vision Dysfunction Market to Reach USD 130 Billion by 2033, Growing at a CAGR of 3.7%

The global age-related vision dysfunction market is poised for steady growth, according to recent market analysis. In 2023, the market was valued at USD 90 billion and is projected to reach a market value of USD 130 billion by 2033, expanding at a Compound Annual Growth Rate (CAGR) of 3.7% over the forecast period.

The increasing prevalence of eye disorders, particularly among the aging population, is expected to drive market growth. As the use of electronic devices continues to rise globally, more individuals are experiencing vision-related issues such as Asthenopia (eye strain). This has led to a surge in demand for vision care products, including eye drops and vision care capsules, as people seek to correct and enhance their eyesight.

With the aging population expanding and lifestyle habits contributing to vision issues, the market for age-related vision dysfunction products is expected to see sustained growth throughout the forecast period.

Furthermore, the rising prevalence of eye illnesses such as diabetic, glaucoma, cataract, and age-related macular degeneration is expected to boost demand for assistive technology in age related vision dysfunction. As a result, the worldwide age related vision dysfunction market will expand. For example, the World Glaucoma Association estimates that 79.6 million people would develop glaucoma by 2020. This figure is expected to rise to 111.8 million by 2040.

According to a United Nations (UN) estimate, the worldwide population of people aged 60 and more was around 962 million in 2017, with a projected increase to 2.1 billion by 2050 According to the National Federation of the Blind, an estimated 3,171,100 persons aged 65 and older in the United States had visual impairment in 2016. All these factors are likely to drive the age related vision dysfunction market during the forecast period

Key Takeaways from the Market Study

FMI projects the global Age Related Vision Dysfunction market to expand at a 3.7% value CAGR by 2033
The global Age Related Vision Dysfunction market is estimated at a market value of US$ 90 Billion
The global Age Related Vision Dysfunction market is expected to garner a market value of US$ 130 Billion
As per Future Market Insights, Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.
As per Future Market Insights, North America is expected to grow at a CAGR of 3.6% in the assessment period 2023-2033.
As per Future Market Insights, Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023-2033.
The glaucoma segment is expected to hold the largest market share for Age Related Vision Dysfunction in the forecast period 2023-2033

“Increased government measures to develop assistive technology and supply assistive technology equipment to the disabled is also predicted to fuel growth in the worldwide age related vision dysfunction market.”Says an analyst at FMI

Market Competition

Aerie Pharmaceuticals
Santen Pharmaceutical
Sun Pharma Advanced Research Company Limited
Bausch + Lomb
D Western Therapeutics Institute
Novartis
AbbVie
Eyenovia
Orasis Pharmaceuticals
IVERIC Bio

A Full Report Overview

Recent Developments:

In May 2020, AbbVie Inc. finalised the strategic acquisition of Allergan plc. As a result of this purchase, AbbVie Inc. has positioned itself as a market leader in the age related vision dysfunction

Key Segments Profiled in the Age Related Vision Dysfunction Market Industry Survey

Age Related Vision Dysfunction Market by Dysfunction Type:

Cataract
AMD
Glaucoma
Presbyopia

Age Related Vision Dysfunction Market by Drug:

Rocklatan
Eybelis Ophthalmic Solution
Xelpros
Rhopressa
Vyzulta
Glanatec
Simbrinza
Tapcom/DE-111
Azarga/Azorga
Combigan
Lucentis
Eylea
Beovu

Age Related Vision Dysfunction Market by Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global Mesotherapy Market to Reach USD 768 Million by 2032, Growing at a CAGR of 17.5%

The global mesotherapy market is set for rapid expansion over the coming decade, according to a recent analysis by Future Market Insights. In 2021, the market was valued at USD 134.2 million, and it is projected to grow at an impressive Compound Annual Growth Rate (CAGR) of 17.5% from 2022 to 2032, reaching a valuation of USD 768 million by 2032.

The Mesotherapy Solutions segment is expected to be the highest revenue-generating category, with an anticipated CAGR of over 21.5% during the forecast period. Mesotherapy has gained significant traction due to its non-invasive nature and applications in skin rejuvenation, fat reduction, and hair loss treatments, driving market growth globally.

As consumer interest in aesthetic procedures and wellness solutions continues to rise, the mesotherapy market is expected to see strong demand, particularly in regions with expanding healthcare infrastructure and increasing disposable incomes.

The report offers extensive data sets validating key trends impacting growth in the Mesotherapy market. It offers insights into strategies adopted by the key players rise and address the concerns that will challenge the growth of Mesotherapy market.

With our extensive research and information about the past, current and future market scenario, the Mesotherapy market report will help and identify the concerns, for a smooth-sail of the small & medium as well as large enterprises.

Mesotherapy Market: Segmentation

By Region

North America
Latin America
Europe
APAC
MEA

Detailed analysis on the geographical region and country wise insights are offered in the latest Mesotherapy market report with established market players as well as incumbents in the region.

A Full Report Overview

Market Segments Covered in Mesotherapy Market Analysis

By Type:

Mesotherapy Solutions
Mesotherapy Masks
Mesotherapy Creams
Mesotherapy Devices
Other Types

By Application:

Anti-aging
Facial Rejuvenation
Stretch Marks
Acne & Scar Treatment
Fat Loss
Hair Loss
Other Applications

By End-use:

Hospitals
Dermatology & Cosmetic Clinics
Other End-uses

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

Competitive Analysis

By Prominent Market Player:

Some of the key companies operating in the mesotherapy market include Koru Pharmaceuticals Co. Ltd., AbbVie Inc., Galderma Laboratories, L.P., Mesoskinline, Institute BCN, Fusion Meso, and Mesoestetic.

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Buttock Augmentation Market is expected to Grow USD 26.9 Billion by 2032 increase at a CAGR of around 27.4%

Global sales of the Buttock Augmentation Market in 2021 were held at USD 1.9 Billion. The market is expected to reach a valuation of USD 26.9 Billion by 2032, with a CAGR of 27.4% between 2022 and 2032. Buttock Implants is expected to be the highest revenue-generating segment, with a CAGR of more than 29.5% between 2022 and 2032.

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Buttock Augmentation market.

FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Buttock Augmentation market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision.

The report offers extensive data sets validating key trends impacting growth in the Buttock Augmentation market. It offers insights into strategies adopted by the key players rise and address the concerns that will challenge the growth of Buttock Augmentation market. With our extensive research and information about the past, current and future market scenario, the Buttock Augmentation market report will help and identify the concerns, for a smooth-sail of the small & medium as well as large enterprises.

A Full Report Overview

Buttock Augmentation Market: Segmentation

Market Segments Covered in Buttock Augmentation Market Analysis

By Product Type:

Buttock Injection
- Hydrogel Butt Injections
- PMMA Buttock Injections
- Poly L-Lactic acid
- Silicone Butt Injections
Buttock Implants
- Silicone gel Implants
- Fat Grafting
Other Product types

By End User:

Hospitals
Aesthetic Clinics
Other end uses

Comprehensive analysis of the regional markets offers exclusive insights on the market performance across geographies along with relevant graphs, figures, and list of tables.

By Region

North America
Latin America
Europe
APAC
MEA

Detailed analysis on the geographical region and country wise insights are offered in the latest Buttock Augmentation market report with established market players as well as incumbents in the region.

Competitive Analysis

By Prominent Market Players

The key players operating in the buttock augmentation market include Sientra Inc., Polytech Health & Aesthetics, Allergan, Hospital Corporation of America, Implantech, Dermax Technology Ltd., and Sebbin.

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Global IgA Nephropathy Market to Reach USD 85 Billion by 2033, Growing at a CAGR of 7.5%

The global IgA nephropathy market is set to experience significant growth over the next decade, with the market expected to be valued at USD 41.24 billion in 2023. According to a new report, the market is projected to expand at a Compound Annual Growth Rate (CAGR) of 7.5%, reaching a valuation of USD 85 billion by 2033.

The rising prevalence of kidney diseases across various age groups is a key driver of the IgA nephropathy market. The market experienced a CAGR of 4.8% during the historical period from 2017 to 2022 and is now on a faster growth trajectory. IgA nephropathy (IgAN) is an autoimmune disorder that primarily affects the kidneys, leading to impaired blood filtration in the small vessels of the organ. The disease occurs when an abnormal protein damages the kidney’s filtering unit, the glomerulus, resulting in pain and the need for various treatment options.

With an increasing global burden of kidney diseases and advancements in treatment approaches, the market for IgA nephropathy is expected to continue its robust growth, providing new opportunities for therapeutic development.

The COVID-19 pandemic has been associated with increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor and availability of dialysis equipment & supplies. In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to temporary closure of other medical services. The diagnosis of several renal diseases deferred during the pandemic due to suspension of non-urgent visits and testing services.

On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for the market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.

Key Takeaways from the Market Study

IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
North America is expected to possess 40% market share for IgA nephropathy market in 2023.
Asia Pacific is expected to hold 35% market share for IgA nephropathy market share in 2023.

“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst

Competitive Landscape

Some of the key companies in the IgA Nephropathy market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others

· In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).

Chinook Therapeutics, Inc, a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global IgA nephropathy market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Diagnosis (Iothalamate Clearance Test, Kidney Biopsy, Blood Tests, Urine Tests) Diseases Type( Primary IgA Nephropathy, Secondary IgA Nephropathy), Systems(Hematuria, Proteinuria, Edema, Others), Population Type (Pediatrics, Adults), Route of Administration (Oral, Parenteral, Others), Treatment (Medication, Statin therapy, Omega-3 fatty acids, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs), Diuretics, Immunosuppressants, Kidney Transplantation, Others), End Users (Hospitals, Specialty Clinics, Homecare, Others) regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

A Full Report Overview

Key Segments Profiled in the IgA Nephropathy Market Survey

Diagnosis:

Iothalamate Clearance Test
Kidney Biopsy
Blood Tests
Urine Tests

Diseases Type:

Primary IgA Nephropathy
Secondary IgA Nephropathy

Systems:

Hematuria
Proteinuria
Edema
Others

Population Type:

Pediatrics
Adults

Route of Administration:

Oral
Parenteral
Others

Treatment:

Medication
Statin therapy
Omega-3 fatty acids
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin receptor blockers (ARBs)
Diuretics
Immunosuppressants
Kidney Transplantation
Others

End Users:

Hospitals
Specialty Clinics
Homecare
Others

Author By:

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us: